COR2ED - Oncology Medical Conversation

Pre-analytical Phase Challenges and Biomarker Testing in HER2+ Metastatic Breast Cancer    Key clinical takeaways:   Metastatic breast cancer (mBC) is a complex, heterogeneous disease requiring multidisciplinary collaboration. Pathologists are central to this process to ensure accurate interpretation and optimal patient management    Incorporating HER2-low and HER2-ultralow categories in biomarker testing is critical for mBC due to the demonstrated efficacy of HER2-targeted antibody-drug conjugates, such as trastuzumab deruxtecan, in these patient subsets, expanding therapeutic options beyond traditional HER2-positive cases    High-quality pre-analytical handling and nuanced interpretation are essential for accurate HER2 classification, particularly for HER2-low and –ultralow disease. Small errors in testing or interpretation can lead to missed treatment opportunities.      This is the full video. Watch the shorter highlights video here: https://cor2ed.com/precision-oncology-connect/programmes/biomarker-testing-breast-cancer/?media=0    Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying one-page snapshot: https://cor2ed.com/precision-oncology-connect/programmes/biomarker-testing-breast-cancer/?media=2     Follow us on social media:  LinkedIn: https://linkedin.com/company/ntrk-connect  X: https://x.com/PresOnc_Connect    This content is intended for healthcare professionals only.   This video is supported by an Independent Education Grant from Daiichi Sankyo.    This video is developed by cor2ed.com  Published on March 2026.    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

Understanding HER2-low and HER2-ultralow classification in mBC In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binary HER2 model translates into everyday clinical practice. The experts explore: Key efficacy data from DESTINY-Breast04 and DESTINY-Breast06, and their impact on the HER2 treatment framework The clinical relevance of HER2-low and HER2-ultralow categories, and review the CAP reporting template When and why to perform re-biopsy to detect changes in HER2 expression over time Best practices for monitoring and managing T-DXd–related adverse events, including nausea, vomiting, fatigue and ILD/pneumonitis   Watch now to deepen your understanding of HER2-low and HER2-ultralow classification, refine how and when you test, and appreciate the impact on therapeutic decision-making in mBC.   Clinical takeaways   DESTINY-Breast04 and DESTINY-Breast-06 established T-DXd as an effective option for HER2-low and HER2-ultralow mBC, improving PFS and OS and showing that even minimal HER2 expression can identify patients who benefit from T-DXd Current CAP reporting template separates HER2-low (IHC 1+ or 2+/ISH–) and HER2-ultralow (IHC 0 with faint or incomplete membrane staining in ≤10% of tumour cells) from true HER2-0, creating treatment-defining strata for HER2-targeted ADCs such as T-DXd Because HER2 expression is dynamic between primary and metastatic sites and over time, re-biopsy at progression, particularly in tumours previously scored as HER2-0, should be considered to identify new candidates for T-DXd T-DXd delivers substantial antitumour activity, but treatment-related adverse events, including nausea, vomiting, fatigue, alopecia and, in particular, ILD/pneumonitis, require careful and proactive management. Clinicians should apply structured supportive care and early, vigilant monitoring to ensure safe and sustained treatment       This is the full video. Watch the shorter highlights video here: https://youtu.be/3xepcF70Ljw   Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website   Follow us on social media: LinkedIn: https://www.linkedin.com/company/breastcancerconnect/ X: https://x.com/BreastCaConnect   This content is intended for healthcare professionals only.   This programme is supported by an Independent Education Grant from AstraZeneca. This podcast is developed by cor2ed.com   Published December 2025   Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressive, and often misunderstood subset of neuroendocrine cancers.   They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches, including DLL3-targeted therapies.   Through both HCP and patient-centred perspectives, the conversation addresses real-world challenges, the importance of support networks, and the growing sense of hope for people affected by this difficult disease.  Key clinical takeaways:   Unlike NETs, EP-NECs are poorly differentiated, high-grade, aggressive, and fast-growing cancers, with a need for more effective treatments While there remains a medical need for effective treatment of EP-NECs, clinical studies with DLL3-targeted agents show promise  Accessing a support network can provide emotional reinforcement and information for patients and their care partners    You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/net-connect/programmes/ep-nec-diagnosis-treatment-support/?media=0  Or watch on YouTube: https://youtu.be/nfng2s3jSw8  Follow us on social media:  LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true   X:https://x.com/net_connectinfo  This podcast is supported by an Independent Education Grant from Boehringer Ingelheim. This podcast is developed by cor2ed.com  Published in November 2025    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety?  In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs.  As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions such as the potential for first-line treatment with radioligand therapy.  Key clinical takeaways:   Pair the right patient with the right treatment using an understanding of the key clinical studies  The role of PRRT as a very effective 2nd-line treatment was consolidated by the COMPETE study data   The best outcomes are achieved through multi-disciplinary collaborations that include the patient     Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying transcript and infographic: https://cor2ed.com/net-connect/programmes/targeted-radiopharmaceutical-treatment-nets/?media=0   Follow us on social media:  LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true   X: https://x.com/net_connectinfo   This content is intended for healthcare professionals only.  This podcast is supported by an Independent Education Grant from ITM.   This podcast is developed by cor2ed.com    Published September 2025 

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall survival without treatment is just a few months but with systemic chemotherapy this can be improved.    This video includes the highlights from a video podcast where medical oncologists Prof Shubham Pant and Prof Efrat Dotan discuss how to choose and optimise the different chemotherapeutic options at first and second line.  Key clinical takeaways:  mPDAC is notoriously aggressive with a poor prognosis. Patients are generally diagnosed with advanced-stage disease and require treatment with chemotherapy as soon as possible Frontline regimens should be individualised based on performance status, comorbidities, and risk of neuropathy; FOLFIRINOX, NALIRIFOX, and gemcitabine/nab-paclitaxel all offer survival benefit with distinct toxicity profiles Choice of 2nd line treatment should be guided by prior regimen and patient fitness Dose modification and alternative scheduling are standard in real-world practice and are used to maintain dose intensity while improving tolerability and reducing adverse events You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/gi-connect/programmes/tackling-mpdac/?media=0  Or watch on YouTube: https://youtu.be/8YxRnjOYUv4  Follow us on social media:  LinkedIn: https://www.linkedin.com/company/giconnect  X: https://x.com/giconnectInfo  This content is intended for healthcare professionals only.  The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Ipsen USA.  This podcast is developed by cor2ed.com  Published May 2025  Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE) and founder of ALK Positive UK.    As a patient advocate as well as a patient herself, Debra brings a wealth of experience and depth of insight into the discussion with Dr Sabari.    Dr Sabari shares his clinical knowledge regarding diagnosis, biomarker testing and treatment of such alterations, together with his own first-hand experience of treating and empowerig patients like Debra in their own treatment journey.  What does the patient pathway look like from both perspectives?  What are the needs of Medical Oncologists and patients when navigating the treatment journey?  What do patients need from their oncologists?  What do oncologists think their patients need from them?  Are these needs matched by the support currently available?    You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/understanding-rare-nsclc-mutations/?media=0  Or watch on YouTube: https://www.youtube.com/watch?v=Z57cUtQx1BE&t    Follow LUNG CONNECT on social media:  X – https://x.com/lung_connect   LinkedIn – https://www.linkedin.com/company/lungconnect/   This content is intended for healthcare professionals only.  The experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Boehringer Ingelheim.    This podcast is developed by cor2ed.com  Published on May 2025    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC  This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.    In this episode Drs Isabel Preeshagul and Eric Singhi provide the benefit of their experience when discussing how to approach different treatment scenarios in HER2-mutant NSCLC.  The conversation unfolds to cover;  How to distinguish HER2 alterations from other alterations on biomarker reports  The latest efficacy and safety data of currently approved and emerging treatments for HER2-altered NSCLC   The potential CNS activity of these treatments in patients with HER2-mutated NSCLC  How the treatment pathway may look in the near future  You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-2/ Or watch on YouTube: https://youtu.be/E8-3GDyJT9Y   Follow LUNG CONNECT on social media:  X – https://x.com/lung_connect   LinkedIn – https://www.linkedin.com/company/lungconnect/   This content is intended for healthcare professionals only.  The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Bayer.    This podcast is developed by cor2ed.com  Published on May 2025    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives  This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.    What makes this conversation so interesting, is that you can gather insights from both the Medical Oncologist perspective with Dr Devika Das, and pathology perspective from Prof. Lopéz-Ríos.  In this episode the discussion focuses identifying HER2-directed NSLC, considering mutations, overexpression and amplifications, whilst not forgetting how best practice in identification of HER2 alterations may be translated in the community setting.  Listen to different expert perspectives on  The different HER2 alterations and prevalence in NSCLC  Which technique to identify which HER2 alteration  HER2-targeted treatments, both approved and in development    You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-1/?media=1  Or watch on YouTube: https://youtu.be/3vMCzR1jqbI    Follow LUNG CONNECT on social media:  X – https://x.com/lung_connect   LinkedIn – https://www.linkedin.com/company/lungconnect/     This content is intended for healthcare professionals only.  The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Bayer.    This podcast is developed by cor2ed.com  Published on April 2025    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase 3 EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups.  Key topics include  Identifying tumors that remain endocrine-sensitive despite acquired resistance to previous ET  Clinical implications of the EMERALD subgroup analyses  Review of elacestrant's safety profile       Clinical takeaways  Duration of prior ET + CDK4/6i ≥12 months was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC endocrine monotherapy in patients with ESR1-mut, ER+/HER2– metastatic breast cancer  The PFS benefit associated with elacestrant was consistent across clinically relevant subgroups evaluated, including patients with bone metastases, liver and/or lung metastases, n<3 or ≥3 metastatic sites or tumors with PIK3CA-mut, TP53-mut, HER2-low tumor expression, or ESR1-mut variants D538G or Y537S/N  Safety analyses demonstrated that elacestrant had a manageable safety profile similar to other ETs and without evidence of the toxicities associated with other drug classes, such as CDK4/6i and PI3K/AKT/mTOR inhibitors  These data support current guidelines that recommend routine testing for the emergence of ESR1-mut in ctDNA at each disease progression    This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.    This video was developed by https://cor2ed.com/      Published March 2025 

This podcast explores the best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer.   Dr Rena Callahan and Dr Roberto Salgado discuss key biomarkers, testing methods, and clinical decision-making, offering expert insights on how to optimise precision medicine.   Topics include liquid vs. tumour biopsy, single gene vs. broad panel testing, and regional differences in testing practices.   Tune in for a practical, expert-led discussion on how molecular testing can guide personalised treatment and improve patient outcomes.    Key clinical takeaways:  Molecular testing, especially for biomarkers like ESR1 and PI3 kinase, is a critical component in guiding treatment decisions, particularly in second-line therapy for HR+ HER2- metastatic breast cancer.  Liquid biopsy is a valuable tool for ongoing monitoring of metastasis and detecting mutations like ESR1 during disease progression, but tissue biopsies may yield more reliable results for certain mutations like PI3 kinase alterations present early in cancer development.  Testing for a broad range of mutations, such as PI3 kinase, AKT, PTEN, ESR1, MSI, and NTRK, allows for the identification of actionable mutations and eligibility for newer targeted therapies, especially in second and third-line treatments.  Clinicians must be familiar with the specifics of the assays used to test for mutations, as different methods and testing conditions can impact results.    You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/precision-oncology-connect/programmes/molecular-testing-targeted-therapy-metastatic-breast-cancer/?media=0 Or watch on YouTube: https://www.youtube.com/watch?v=CTnXmh1oDwQ Follow us on social media:  LinkedIn: https://www.linkedin.com/company/ntrk-connect/   X: https://x.com/PresOnc_Connect   This content is intended for healthcare professionals only.  The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Thermo Fisher Scientific.  This podcast is developed by cor2ed.com  Published March 2025  Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions   Key clinical takeaways:   MMR status should be tested in all patients at diagnosis and upon disease progression to guide personalised treatment decisions   ICI and ChT combination, including with maintenance olaparib, demonstrates benefits in patients with non-dMMR advanced/recurrent endometrial cancer, with greater efficacy observed in dMMR populations  Lenvatinib plus pembrolizumab is a viable option not only as 2nd line therapy but also as 1st line treatment for patients with non-dMMR advanced/recurrent endometrial cancer who have progressed after prior systemic therapy in any setting  Shared decision-making, supported by patient education, is essential for optimising treatment outcomes   The treatment landscape for advanced and recurrent endometrial cancer (EC) is evolving, with molecular classification playing a key role in guiding decisions. In this podcast, Prof. Xavier Matias-Guiu (Pathologist) and Dr Jurjees Hasan (Medical Oncologist) discuss the latest advancements in personalised treatment approaches for EC.  Key topics include:  The role of molecular classification in guiding treatment selection and testing strategies  Treatment options for patients with pMMR status  Effective patient communication for shared decision-making  Tune in for expert insights and practical guidance to optimise treatment strategies in advanced and recurrent EC  You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/obstetrics-gynecology-connect/programmes/endometrial-cancer-molecular-classification-treatment-decisions/  Or watch on YouTube: https://youtu.be/KvYIB7PBpyQ    Follow us on social media:  LinkedIn: https://www.linkedin.com/company/ob-gyn-connect/?viewAsMember=true   X: https://x.com/OBGynConnect     This content is intended for healthcare professionals only.  The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this podcast.    This podcast is developed by cor2ed.com  Published February 2025    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

Intermediate HCC – The evolving role of IO  In this final episode of the four-part series on hepatocellular carcinoma (HCC), hosted by the Oncology Brothers Drs Rohit and Rahul Gosain, the discussion focuses on the evolving role of immunotherapy (IO) in intermediate HCC. The episode explores multimodal approaches that combine IO and IO-based therapies with loco-regional treatments and highlights the essential role of a multidisciplinary care team.   Joined by Drs Nina Sanford (radiation oncologist), Mark Yarchoan (medical oncologist) and Ed Kim (interventional radiologist), the experts provide a brief overview of current treatment options for intermediate HCC, addressing its heterogeneity and standard treatment pathways. They delve into the latest clinical trial data (EMERALD-1, LEAP-012) on combining IO with loco-regional therapies, discussing clinical implications. The conversation also underscores the importance of effective collaboration within the multidisciplinary team for delivering optimal patient care. The episode concludes with future perspectives in the field and key clinical takeaways on integrating IO with loco-regional therapy and the significance of multidisciplinary care in managing HCC.  Key clinical takeaways:   IO and IO-based treatments are moving earlier in the treatment paradigm for patients with intermediate HCC. Earlier integration of these therapies aims to achieve improved systemic control, allowing loco-regional therapy to target oligoprogression, residual lesions or reduce tumour burden    Emerging data supports combining systemic and loco-regional therapies for patients with intermediate HCC. EMERALD-1 and LEAP-012 show promising PFS data using IO-based combination regimens like durvalumab + bevacizumab or pembrolizumab + lenvatinib alongside TACE. Long-term OS data are awaited    Effective communication and coordinated care among specialists, such as medical oncologists, radiation oncologists, hepatologists, and interventional radiologists, are essential to developing optimal treatment strategies for patients with intermediate HCC      You can also watch a video of the experts in conversation and download the accompanying slides and transcript on our website: https://cor2ed.com/hcc-connect/programmes/intermediate-hcc-the-evolving-role-of-io/  Or watch on YouTube: https://www.youtube.com/watch?v=3voWa0U96lE    Follow us on social media:  LinkedIn: https://www.linkedin.com/company/hcc-connect/ X https://x.com/hccconnectinfo     This content is intended for healthcare professionals only.   The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. AstraZeneca has provided a sponsorship grant towards this independent programme.  This podcast is developed by cor2ed.com  Published on January 2025  Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. <...

In the third of this 4-part podcast series on HCC, the Oncology Brothers Dr Rahul and Dr Rohit Gosain are joined by Hepatologist Dr Maria Reig and Interventional Radiologist Dr Emil Cohen to explore the complexities of managing intermediate-stage hepatocellular carcinoma (HCC). Together, they unpack treatment options and strategies through a dynamic and engaging discussion rooted in real-world clinical practice.  Key topics include:  An overview of the available treatment options for this heterogeneous patient population with intermediate HCC  A deep dive into loco-regional therapies, including TACE, TARE (Y-90), and SBRT  Exploring the role of systemic treatments in patients with intermediate HCC and the use of multimodal treatment approaches, combining loco-regional treatment options with systemic treatments  The importance of the multidisciplinary care team for the treatment of intermediate HCC    Key clinical takeaways:   Defined by guidelines, treatment options for patients with intermediate HCC include liver transplantation, loco-regional therapies, and systemic therapy. Treatment selection depends not only on tumour burden and liver function, but also on practical considerations in clinical practice  Systemic therapies are being evaluated earlier in the disease course, particularly for intermediate HCC, either as standalone treatments or in combination with loco-regional therapies  Ongoing clinical trials, such as REPLACE and ABC-HCC, aim to clarify the role of systemic therapies in intermediate HCC as standalone options, while others, like EMERALD-1 and LEAP-012, focus on their use in combination with loco-regional approaches  Adverse events require identification of the specific adverse events profile. Regardless of origin (systemic or loco-regional), complications must be resolved to maintain treatment efficacy and ensure patient safety  Optimal care for intermediate HCC relies on a multi-disciplinary team, including hepatologists, interventional radiologists, radiation oncologists, surgeons, and medical oncologists      Prefer to watch the experts in conversation? Go to the video on our website: https://cor2ed.com/hcc-connect/programmes/advanced-hcc-treatment-selection/     Follow us on social media:  LinkedIn: https://www.linkedin.com/company/hcc-connect   X: https://x.com/hccconnectinfo     This content is intended for healthcare professionals only.   The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.    This podcast is developed by cor2ed.com  Published January 2024    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

Join the Oncology Brothers, Drs Rahul and Rohit Gosain, as they host an insightful discussion with Dr Lorenza Rimassa and Prof. Arndt Vogel. In the second of a 4-part podcast series, this episode dives into 2nd line treatment selection in advanced HCC and the key considerations for deciding when to switch therapies.    Topics include:  2nd line options for advanced HCC after 1st line TKIs and IO-based therapies  Sequencing strategies and clinical practice approaches  Key data supporting 2nd line decisions  Factors to consider when transitioning to 2nd line therapy    Key clinical takeaways:   Prospective Phase 3 data on 2nd line options in advanced HCC, particularly after immunotherapy, is limited, highlighting the need for further evidence to guide optimal treatment decisions  When switching to 2nd line therapy, it is essential to evaluate all the available treatment options to ensure the optimal choice for each patient, considering efficacy, tolerability, liver function, and quality of life.  Switching to 2nd line therapy should be considered in cases of clear disease progression, such as the appearance of new lesions outside the liver. Best supportive care should also be considered  Managing side effects of 2nd line treatments (e.g. hypertension, skin toxicity, proteinuria) is critical for maintaining quality of life and providing optimal disease management  Effective management requires a multidisciplinary team effort, including oncologists, hepatologists, interventional radiologists, and other specialists to optimise outcomes and proactively manage symptoms like hepatic decompensation      Prefer to watch the experts in conversation? Go to the video on our website: https://cor2ed.com/hcc-connect/programmes/advanced-hcc-treatment-selection/     Follow us on social media:  LinkedIn: https://www.linkedin.com/company/hcc-connect   X: https://x.com/hccconnectinfo     This content is intended for healthcare professionals only.   The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.    This podcast is developed by cor2ed.com  Published December 2024    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

 Testing to treatment of BRAF-mutant metastatic NSCLC    In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of BRAF mutations in metastatic non-small cell lung cancer (NSCLC), the testing strategies and first- and second-line treatment options for these patients.   The discussion focuses on which BRAF mutations to test for and when in the patient journey to test, before moving on to consider if NGS broad panel testing should be applied routinely for patients.  Various treatments are considered, along with which decision criteria come into play when selecting a particular treatment.   The experts also discuss how to treat patients who have co-mutations detected during testing.  This is an informative podcast that culminates in some interesting key messages from two well-recognised Experts in the field of NSCLC.      Key clinical takeaways:   Test all patients irrespective of histology and smoking history  Test upfront so that more efficacious agents can be used earlier in the patient journey  Next-generation sequencing is the gold-standard for testing wherever possible to ensure various targetable alterations are not missed  There are effective BRAF + MEK inhibitor combination treatments available to treat our BRAFv600E-mutant metastatic NSCLC patients which have manageable safety profiles    Would you prefer to watch the experts in conversation? This podcast episode is also available in video format, here: https://youtu.be/UZPBUAFOwcY Download the trasncript and find out more about this programme and the featured experts here: https://cor2ed.com/lung-connect/programmes/testing-treatment-braf-mutant-metastatic-nsclc/   Follow us on social media:  LinkedIn: https://www.linkedin.com/company/lungconnect/   X: https://x.com/lung_connect     This content is intended for healthcare professionals outside of the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. This podcast is developed by https://cor2ed.com/  Published November 2024    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

In the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the use of IO (immunotherapy) in unresectable HCC (uHCC) and take a deep dive into the different treatment options first-line focusing on IO and IO based combinations. Topics include:    Current first-line systemic treatment options for uHCC  Efficacy and safety of IO and IO combinations including practical aspects of identifying and managing immune-mediated AEs  How to select between the two first-line IO-based treatment options based on clinical factors and practical considerations     Key clinical takeaways: Two first-line IO and IO-based combinations are approved for patients with unresectable hepatocellular carcinoma (HCC), with ongoing advancements shaping the treatment landscape  Clinical trials in newly diagnosed unresectable HCC patients have validated the effectiveness of IO plus anti-VEGF (atezolizumab + bevacizumab, IMbrave150) and dual IO (tremelimumab + durvalumab, HIMALAYA) approaches, establishing the proof of principle for these strategies  Landmark analysis is critical in IO-based treatments due to the delayed and continued separation of survival curves. Notably, the STRIDE regimen ( single tremelimumab regular interval durvalumab) shows one in five patients achieving five-year survival in long-term follow-up  IO and IO-based regimens for unresectable HCC are generally well-tolerated, with immune-related adverse effects manageable using steroids when necessary.  In clinical practice, treatment choice should be individualized, taking into account factors such as potential side effects and logistical considerations, including the frequency of hospital visits      Follow us on social media:  LinkedIn: https://www.linkedin.com/company/hcc-connect   X: https://x.com/hccconnectinfo     This content is intended for healthcare professionals only.   The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. AstraZeneca has provided a sponsorship grant towards this independent programme.    This podcast is developed by cor2ed.com  Published on November 2024    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

Experts Prof. Sebastian Stintzing and Dr Thomas Winder discuss the significance of BRAF mutations in colorectal cancer (CRC), and the testing strategies and available treatments for these patients.     They consider the prevalence and types of BRAF mutations in CRC patients and highlight the poor prognosis for these patients. The experts also cover the optimal time and methods for testing for BRAF mutations, as well as the targeted therapies currently available for BRAF-mutated CRC.     Several key trials are discussed, including the BEACON trial which resulted in encorafenib plus cetuximab being the standard of care in the second-line setting for patients with BRAF mutated CRC.     The discussion also looks at future studies including the BREAKWATER trial, which will provide important information about encorafenib plus cetuximab in the first-line for these patients, as well as the SEAMARK trial which will show the effects of adding immunotherapy to this combination.      Key clinical takeaways:  BRAF mutations occur in around 10% of colorectal cancer patients and patients harbouring these have aggressive disease and a poor prognosis  Targeted therapies are available for BRAF-mutated CRC so it is important to test patients early in their disease preferably with next-generation sequencing  Encorafenib plus cetuximab are established as the standard of care in the second-line setting for BRAF-mutated CRC  Doublet chemotherapy plus anti-VEGF is currently the preferred treatment in the first-line. The BREAKWATER trial will determine whether the combination of encorafenib plus cetuximab is a suitable first-line treatment option    Would you prefer to watch the experts in conversation? This podcast episode is also available in video format, here: https://youtu.be/Pp7oAI9JW4A  Download the transcript and find out more about this programme and the featured experts here: https://cor2ed.com/gi-connect/programmes/braf-mutated-crc-testing-treatment/    Follow us on social media:  LinkedIn: https://www.linkedin.com/company/giconnect    X: https://x.com/giconnectInfo     This content is intended for healthcare professionals outside of the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. This podcast was developed by https://cor2ed.com/   Published November 2024

In this second episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins explore shared decision-making, between patient and physician.     The speakers discuss different treatment settings, including home vs hospital-based injections, as well as the importance of individualising treatment decisions, as there is often no standard therapy for patients with NETs. Finally, they look at some of the studies reporting patient preferences, and how the data can be used to inform patient decisions.    Prefer to watch and listen? Watch the video and download the full transcript on the COR2ED website https://cor2ed.com/net-connect/programmes/net-shared-decision-making/?media=1  Watch the full video on YouTube https://youtu.be/2JYuPhc2jHg  Watch the highlights video on YouTube – https://www.youtube.com/watch?v=pPMVLjPLv8k     Follow us on social media  LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect   X: https://x.com/net_connectinfo     This content is intended for healthcare professionals only.  The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Medical Education Grant from Ipsen  This podcast is developed by cor2ed.com  Published July 2024 

In this first episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins discuss the importance of communication and collaboration during consultations. This can include how to make a patient feel as comfortable and in control as possible, as well as recognising their goals and concerns.     The speakers share their real-life experiences of what makes a good consultation, from the perspectives of both a patient and a physician. They also explore the importance of support networks, individualising treatment, and the impact of NET and NET treatment options in daily life.     NETs are complex, rare diseases. Optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. Are you aware of how healthcare practitioners and patients can share decision- making? Or the recent data on how patients prefer to receive treatment?     In this first episode of a two-part podcast series, Dr Mohid S Khan and NET patient Sally Jenkins discuss shared decision-making in NET consultations and ways to help the patient in their journey.    Prefer to watch and listen? Watch the video and download the full transcript on the COR2ED website https://cor2ed.com/net-connect/programmes/net-shared-decision-making/ Watch the full video on YouTube https://youtu.be/YgqrEnSePWg Watch the highlights video on YouTube – https://www.youtube.com/watch?v=pPMVLjPLv8k   Follow us on social media  LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect   X: https://x.com/net_connectinfo     This content is intended for healthcare professionals only.  The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen  This podcast is developed by cor2ed.com  Published July 2024 

In the second episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss how to optimize treatment for people living with NETs and future developments in the field which may help to improve patient outcomes. The episode includes information on different treatment options and modalities, and well as best practice on identifying which patients may benefit most from particular treatments using available biomarkers.    Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neuroendocrine Tumour Society’s Centre of Excellence” and the UCL Academic Neuroendocrine Tumour Unit, which includes leading scientific and clinical research programmes into NETs. Prof. Rachel Riechelmann is a medical oncologist and clinical scientist focused on colorectal/anal cancers and NETs. Director of the Clinical Oncology Department, AC Camargo Cancer Center, in Sao Paulo, Brazil and is Head of the Neuroendocrine Tumors Reference Center.      Prefer to watch as well as listen?    Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/net-connect/programmes/regional-differences-neuroendocrine-tumours-nets-2/       Or go to the video on YouTube: https://youtu.be/zd_JvUmIhFg      We are pleased to share that this podcast is endorsed by the North American Neuroendocrine Tumor Society (NANETS). You can find out more about NANETS at https://nanets.net/     The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen.    This podcast is developed by cor2ed.com

In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, and patient pathways, as well as look to future developments.   NETs are complex, rare diseases. Their optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. The best possible patient journey is impacted by regional differences in management strategies, referral pathways, and availability of diagnostic modalities and treatments.. Are you aware of the epidemiology of NETs and current best practices for diagnosis, referral strategies, and treatment for NETs? Or how regional differences can impact these? In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, patient pathways, as well as look to future developments.     Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neuroendocrine Tumour Society’s Centre of Excellence” and the UCL Academic Neuroendocrine Tumour Unit, which includes leading scientific and clinical research programmes into NETs. Prof. Rachel Riechelmann is a medical oncologist and clinical scientist focused on colorectal/anal cancers and NETs. Director of the Clinical Oncology Department, AC Camargo Cancer Center, in Sao Paulo, Brazil and is Head of the Neuroendocrine Tumors Reference Center.    Prefer to watch as well as listen?    Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/net-connect/programmes/regional-differences-neuroendocrine-tumours-nets-1/       Or go to the video on YouTube: https://youtu.be/6fKAxS4u-2o      We are pleased to share that this podcast is endorsed by the North American Neuroendocrine Tumor Society (NANETS). You can find out more about NANETS at https://nanets.net/     The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen.    This podcast is developed by cor2ed.com 

Do you understand the needs of different patient groups with colorectal cancer?  Do you know about the barriers to treatment experienced by different ethnicities, socioeconomic groups and younger patients?  In this insightful podcast facilitated by Oncology Brothers Drs Rahul and Rohit Gosain, Prof Tanios Bekaii-Saab and Ms Deneen Richmond provide their perspectives as a practising oncologist and a cancer survivor. They discuss the different methods of communication required to build trust in patients from specific ethnic groups (African American, Hispanic and Asian American).  They also talk about the unique challenges experienced by younger patients with colorectal cancer.  Throughout the podcast the experts emphasise the importance of screening to facilitate early diagnosis and treatment. Prefer to watch as well as listen? Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/gi-connect/programmes/patient-populations-colorectal-cancer/ Or go to the video on YouTube: https://youtu.be/o-lr54-D9_g The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer. This educational podcast is developed by cor2ed.com

What are the challenges and considerations when using real-world evidence to inform your clinical practice? How can data from real-world studies be used to complement data from clinical trials?    In this podcast, GI oncologists Prof. Tanios Bekaii-Saab and Prof. Shubham Pant discuss how to interpret real-world evidence in later line metastatic colorectal cancer.  They also discuss data from ASCO GI 2024 and how these results can be used to inform treatment decisions.    Prefer to watch as well as listen?    Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/gi-connect/programmes/real-world-evidence-mcrc/   Or go to the video on YouTube: https://youtu.be/knQcsWVqcSA   The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.  This educational podcast is developed by cor2ed.com 

¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de ovario, y cómo podemos solucionarlos? ¿Por qué es importante identificar las alteraciones genéticas?   Usted está viendo el tercer episodio de una serie de podcast de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.   En este episodio, escuchará a la profesora adjunta Martina Murphy (médica oncóloga) y a la profesora adjunta Caterina Marchiò (anatomopatóloga) hablar sobre las dificultades en la fase preanalítica y las pruebas de biomarcadores en el cáncer de ovario.   A medida que se desarrolla la conversación, las expertas explican por qué es tan importante identificar las alteraciones genéticas en el cáncer de ovario y hablan sobre los mejores métodos para minimizar las dificultades preanalíticas.   ¿Prefiere ver el video mientras escucha?   Vea el video de la conversación de los expertos y descargue la transcripción completa en el sitio web de COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-ovario-dificultades-en-la-fase-preanalitica-y-pruebas-de-biomarcadores/   O acceda al video en YouTube: https://youtu.be/HnYacC0wZp0   Nos complace compartir que este pódcast cuenta con el apoyo de la Asociación para la Patología Molecular (AMP). Puede obtener más información sobre la AMP en www.amp.org.   Los expertos médicos en este podcast expresan sus propias opiniones y no las de COR2ED, sus colaboradores ni su institución. Este pódcast cuenta con el apoyo de una subvención educativa médica independiente de AstraZeneca y Amoy Diagnostics. Este podcast fue creado por cor2ed.com

Quais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de ovário e como podemos superá-los? Qual a importância de detectar alterações genéticas?   Você está assistindo à parte 3 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.   Neste episódio, você ouvirá a Professora Adjunta Martina Murphy (oncologista) e a Professora Adjunta Caterina Marchiò (patologista) esclarecerem quais são os desafios da fase pré-analítica e do teste de biomarcadores para câncer de ovário.   Ao longo da conversa, os especialistas explicam o porquê é tão importante identificar alterações genéticas no câncer de ovário e conversam sobre as melhores práticas de abordagem que auxiliam na diminuição dos desafios na fase pré-analítica.   Prefere assistir enquanto escuta?   Assista ao vídeo da conversa dos especialistas e baixe a transcrição completa no site da COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-ovario-desafios-da-fase-pre-analitica-e-teste-de-biomarcadores/   Ou veja o vídeo no YouTube: https://youtu.be/tiUgtzqMD-Q   Temos o prazer de compartilhar que este podcast tem o endosso da Associação pela Patologia Molecular (AMP). Saiba mais sobre a AMP em www.amp.org   Neste podcast, os médicos especialistas expressam suas visões e não as da COR2ED, seus financiadores nem suas instituições. Este podcast é financiado por uma Bolsa Médica Educacional Independente concedida pela AstraZeneca e Amoy Diagnostics. Este podcast é desenvolvido pela cor2ed.com

¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de próstata, y cómo podemos superarlos? ¿Por qué es importante identificar las alteraciones genéticas?   Está escuchando la parte 1 de una serie de podcast en video de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.   En este episodio, escuchará al especialista en genómica del cáncer genitourinario, el Dr. Alexander Wyatt, y al oncólogo médico, el Dr. Petros Grivas, profundizar sobre las dificultades en la fase preanalítica y las pruebas de biomarcadores en el cáncer de próstata.   A medida que se desarrolla la conversación, los expertos explican por qué es tan importante identificar las alteraciones genéticas en el cáncer de próstata y hablan sobre los mejores métodos prácticos que contribuyen a minimizar las dificultades preanalíticas. ¿Prefiere ver el video mientras escucha?   Vea el video de la conversación de los expertos y descargue la transcripción completa en el sitio web de COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-prostata-dificultades-en-la-fase-preanalitica-y-pruebas-de-biomarcadores/   O acceda al video en YouTube: https://youtu.be/WR9pX3kNao0   Nos complace compartir que este pódcast cuenta con el apoyo de la Asociación para la Patología Molecular (AMP) y de la Asociación Nacional de Coaliciones de Cáncer de Próstata (NASPCC). Puede obtener más información sobre la AMP en https://amp.org y la NASPCC en https://naspcc.org.   Los expertos médicos en este podcast expresan sus propias opiniones y no las de COR2ED, sus colaboradores ni su institución. Este pódcast cuenta con el apoyo de una subvención educativa médica independiente de AstraZeneca y Amoy Diagnostics.   Este pódcast fue creado por cor2ed.com

Quais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de próstata e como podemos superá-los? Qual a importância de detectar alterações genéticas?   Você está ouvindo a parte 1 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.   Neste episódio, você ouvirá o especialista em genoma do câncer geniturinário, Dr. Alexander Wyatt, e o oncologista, Dr. Petros Grivas, esclarecerem quais são os desafios da fase pré-analítica e do teste de biomarcadores para câncer de próstata.   Ao longo da conversa, os especialistas explicam o porquê é tão importante identificar alterações genéticas no câncer de próstata e conversam sobre as melhores práticas de abordagem que auxiliam na diminuição dos desafios na fase pré-analítica. Prefere assistir enquanto escuta?   Assista ao vídeo da conversa dos especialistas e baixe a transcrição completa no site da COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-prostata-desafios-da-fase-pre-analitica-e-teste-de-biomarcadores/   Ou veja o vídeo no YouTube: https://youtu.be/Pp-2qMSaOPU   Temos o prazer de compartilhar que este podcast tem o endosso da Associação pela Patologia Molecular (AMP) e da Aliança Nacional das Coalizões Estaduais de Câncer de Próstata (NASPCC). Saiba mais sobre a AMP em https://amp.org e sobre a NASPCC em https://naspcc.org   Neste podcast, os médicos especialistas expressam suas visões e não as da COR2ED, seus financiadores nem suas instituições. Este podcast é financiado por uma Bolsa Médica Educacional Independente concedida pela AstraZeneca e Amoy Diagnostics.   Este podcast é desenvolvido pela cor2ed.com

¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de pulmón, y cómo podemos superarlos? ¿Por qué es importante identificar las alteraciones genéticas?   Está viendo la parte 2 de una serie de podcast en video de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.   En este episodio, escuchará a la Dra. Bruna Pellini (médica oncóloga) y al Dr. Semir Vranić (anatomopatólogo) profundizar sobre las dificultades en la fase preanalítica y las pruebas de biomarcadores del cáncer de pulmón.   A medida que se desarrolla la conversación, los expertos explican por qué es tan importante identificar las alteraciones genéticas en el cáncer de pulmón y hablan sobre los mejores métodos prácticos que contribuyen a minimizar las dificultades preanalíticas. ¿Prefiere ver el video mientras escucha?   Vea el video de la conversación de los especialistas y descargue la transcripción completa en el sitio web de COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-pulmon-dificultades-en-la-fase-preanalitica-y-pruebas-de-biomarcadores/   O acceda al video en YouTube: https://youtu.be/LSyhFcVatSI   Nos complace compartir que este pódcast cuenta con el apoyo de la Asociación para la Patología Molecular (AMP). Puede obtener más información sobre la AMP en www.amp.org.   Los expertos médicos en este pódcast expresan sus propias opiniones y no las de COR2ED, sus colaboradores ni su institución. Este pódcast cuenta con el apoyo de una subvención educativa médica independiente de AstraZeneca y Amoy Diagnostics. Este pódcast fue creado por cor2ed.com

Quais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de pulmão e como podemos superá-los? Qual a importância de detectar alterações genéticas?   Você está assistindo à parte 2 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.   Neste episódio, você ouvirá a Dra. Bruna Pellini (oncologista) e Semir Vranić (patologista) esclarecerem quais são os desafios da fase pré-analítica e do teste de biomarcadores para câncer de pulmão.   Ao longo da conversa, os especialistas explicam o porquê é tão importante identificar alterações genéticas no câncer de pulmão e conversam sobre as melhores práticas de abordagem que auxiliam na diminuição dos desafios na fase pré-analítica. Prefere assistir enquanto escuta?   Assista ao vídeo da conversa dos especialistas e baixe a transcrição completa no site da COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-pulmao-desafios-da-fase-pre-analitica-e-teste-de-biomarcadores/   Ou veja o vídeo no YouTube: https://youtu.be/lmwt0UVitF4   Temos o prazer de compartilhar que este podcast tem o endosso da Associação pela Patologia Molecular (AMP). Saiba mais sobre a AMP em www.amp.org   Neste podcast, os médicos especialistas expressam suas visões e não as da COR2ED, seus financiadores nem suas instituições. Este podcast é financiado por uma Bolsa Médica Educacional Independente concedida pela AstraZeneca e Amoy Diagnostics. Este podcast é desenvolvido pela cor2ed.com

What treatment options are available for patients with metastatic colorectal cancer who have already progressed through multiple lines of therapy?  How can we select the right treatment for the right patient?  Medical oncologists Assoc. Prof. Gerald Prager (Austria) and Dr Victor Hugo Fonseca de Jesus draw from their own clinical expertise and data from clinical trials to provide their perspectives on these questions.  They discuss how to manage side effects from available treatments to maximise survival benefit whilst maintaining quality of life and consider what the future holds for later-line treatment in metastatic colorectal cancer. Prefer to watch as well as listen? Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/gi-connect/programmes/patient-outcomes-mcrc/ Or go to the video on YouTube: https://youtu.be/ftjskGynDIc We are pleased to share that this podcast is endorsed by Bayer The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer. This educational podcast is developed by cor2ed.com

Why is it important to perform comprehensive molecular testing in non-small cell lung cancer to look beyond the obvious mutations? Which biomarker tests are best andwhen should testing be performed? In this podcast episode, you’ll hear Prof. Mark Socinski (medical oncologist) and Prof. Frédérique Penault-Llorca (pathologist) discuss why perseverance with molecular testing pays off in non-small cell lung cancer (NSCLC). As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in NSCLC, which biomarker testing approaches should be considered standard of care, and the importance of close collaboration with the pathologist and other members of the multidisciplinary team for optimal patient care. Prefer to watch as well as listen? Watch a video of the experts in conversation and download the full transcript on the COR2ED website:https://cor2ed.com/precision-oncology-connect/programmes/precision-oncology-nsclc/ Or go to the video on YouTube: https://youtu.be/Gn_sjyexreM The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer. This podcast is developed by cor2ed.com

What are the common pre-analytical phase challenges in ovarian cancer, and how can we overcome them? Why is it important to identify genetic alterations?   You are watching part 3 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs Rohit and Rahul Gosain.   In this episode, you’ll hear Assoc. Prof. Martina Murphy (medical oncologist) and Assoc. Prof. Caterina Marchiò (pathologist) shine a spotlight on the pre-analytical phase challenges and biomarker testing in ovarian cancer.   As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in ovarian cancer and discuss best practice approaches to help minimise pre-analytical challenges.   Prefer to watch as well as listen?   Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/ovarian-cancer-preanalytical-challenges-biomarker/   Or go to the video on YouTube: https://youtu.be/EabQZ4CKf5s   We are pleased to share that this podcast is endorsed by the Association for Molecular Pathology (AMP). You can find out more about AMP at www.amp.org   The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from AstraZeneca and Amoy Diagnostics. This podcast is developed by cor2ed.com.

What are the common pre-analytical phase challenges in lung cancer, and how can we overcome them? Why is it important to identify genetic alterations? You are watching part 2 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs Rohit and Rahul Gosain. In this episode, you’ll hear Dr Bruna Pellini (medical oncologist) and Semir Vranić (pathologist) shine a spotlight on the pre-analytical phase challenges and biomarker testing in lung cancer. As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in lung cancer and discuss best practice approaches to help minimise pre-analytical challenges. Prefer to watch as well as listen?  Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/lung-cancer-preanalytical-challenges-biomarker/ Or go to the video on YouTube: https://youtu.be/OG7pWLZ5KMk We are pleased to share that this podcast is endorsed by the Association for Molecular Pathology (AMP). You can find out more about AMP at www.amp.org The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from AstraZeneca and Amoy Diagnostics. This podcast is developed by cor2ed.com.

Treatment of advanced colorectal cancer should be considered a continuum of care and patients should be offered as many life prolonging therapies as possible.  Do you know how to sequence later line therapies in metastatic colorectal cancer? In this podcast, gastrointestinal oncologists Dr Thomas Winder (Austria and Switzerland) and Dr Mark Lewis (USA) discuss the treatment of metastatic colorectal cancer, third line and beyond.  They discuss the sequence of later line treatments regorafenib, TAS-102, bevacizumab and fruquintinib and refer to key clinical trials such as SUNLIGHT, CORRECT, RECOURSE, FRESCO-2 and ReDOS.  They emphasise the importance of balancing treatment efficacy whilst considering adverse event profiles to maintain the patient’s quality of life.  The experts also discuss biomarkers used in a number of molecularly selected trials such as HER2 in the HERACLES (trastuzumab plus lapatininb), MOUNTAINEER (tucatinib plus trastuzumab) and DESTINY-CRC02 (trastuzumab deruxtecan) studies and KRAS G12c in the CODEBREAK 300 study (sotorasib plus panitumumab).

What are tumour agnostic cancer treatments and which biomarkers do they target? Join Prof. David Hong (Medical Oncologist at MD Anderson Cancer Center, Houston, Texas, United States) and Dr Tracy L Stockley (Pathologist and Geneticist at University Health Network, Toronto, Canada) as they deep dive into the topic of tumour agnostic therapies in this video podcast. As the conversation unfolds, the precision oncology experts explore the issues and challenges associated with developing tumour agnostic therapies and discuss how these treatments differ from others. Listen to deepen your understanding of: Biomarker targets associated with tumour agnostic therapies Which tumours carry these gene alterations Appropriate genetic testing strategies to detect these biomarkers  Prefer to watch as well as listen? Watch a video of the experts in conversation and get the clinical takeaways and podcast transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/tumour-agnostic-therapies/ Or go to the video on YouTube: https://www.youtube.com/watch?v=AO33Yv0RTVs Find out more about the experts Prof. David Hong and Dr Tracy L Stockley The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer and is developed by cor2ed.com.

What are the common pre-analytical phase challenges in prostate cancer, and how can we overcome them? Why is it important to identify genetic alterations? You are listening to part 1 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs. Rohit and Rahul Gosain. In this episode, you’ll hear GU cancer genomics expert Dr Alexander Wyatt and medical oncologist Dr Petros Grivas shine a spotlight on the pre-analytical phase challenges and biomarker testing in prostate cancer. As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in prostate cancer and discuss best practice approaches to help minimise pre-analytical challenges. Prefer to watch as well as listen? Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/prostate-cancer-preanalytical-challenges-biomarker/ Or go to the video on YouTube: https://www.youtube.com/watch?v=Sxzw1SX3nao We are pleased to share that this podcast is endorsed by the Association for Molecular Pathology (AMP) and The National Alliance of State Prostate Cancer Coalitions (NASPCC). You can find out more about AMP at https://amp.org and NASPCC at https://naspcc.org The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from AstraZeneca and Amoy Diagnostics. This podcast is developed by cor2ed.com.

In this podcast, Prof. Andra H. James (Professor Emeritus of Obstetrics and Gynecology, Division Maternal Fetal Medicine, Duke University Hospital, Durham, North Carolina, US) and Dr Maria Elisa Mancuso (Senior Haematology Consultant at the Center for Thrombosis and Hemorrhagic Diseases of IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy) discuss various treatment options for severe postpartum haemorrhage (also called PPH). Experts discuss what causes PPH and how to determine the risk before and during labour with algorithms and other helpful tools. The discussion moves to when haematologic expertise is required and how collaboration can be optimized to provide the best care for patients. Furthermore, the experts share their learnings from clinical practice through discussion of specific patient cases, including patients with and without underlying bleeding disorders, as well as where haemostatic agents fit in the protocol.

In this podcast episode, Prof Dimitrios Tsakiris (Haematologist, Basel University, Switzerland) and Dr Lars Asmis (Haematologist, University of Zurich, Switzerland) discuss the association between thrombosis and cancer.  Experts discuss how different tumours affect the risk for thrombosis in patients and genetic disorders such as thrombophilia. They cover multiple scores (Khorana, Vienna, PROTECHT and Pabinger) that might help to categorise thrombosis risk in oncology patients. The discussion moves to how cancer patients with thrombosis should be treated and the duration of treatment of low molecular weight heparins and direct oral anticoagulants (DOACs), with reference to the CLOT study and recent guidelines. In addition, they discuss whether there should be a different approach with hospital in- and out-patients  Finally, both experts discuss anticoagulation and oncocardiology and the higher incidences of atrial fibrillation reported in cancer patients.

Prof. Dr Amit Singal, Gastroenterologist and Hepatologist at UT Southwestern Medical Center, USA and Prof. Dr Jeroen Dekervel, GI Oncologist at UZ Leuven, Belgium, discuss the new era in treating patients with advanced HCC, focusing on treatment selection and the right time to switch to 2nd line therapy. In this podcast, the experts give an overview of the current 1st and 2nd line systemic treatment options and sequences for patients with advanced HCC by looking into the results from different clinical trials and current guidelines. They also shine a light on the differences in approved 2nd line systemic therapies between Europe and USA. The experts present their approach in making the decision to switch to 2nd line therapy, thereby taking toxicity, liver function and disease progression into account. They also discuss the need for comparative effectiveness data to determine the optimal 2nd line therapy.

In this final episode, the experts discuss two patient case studies with oral SERDs (oral selective estrogen receptor degraders) and a novel therapy for ER+/HER2- advanced or metastatic breast cancer. Each patient presents unique and rare situations that shed light on the challenges confronting healthcare professionals and patients alike. They discuss the most up-to-date data and strategies for optimising treatment selection in each individual case. This podcast is a conversation between two independent experts: Dr. Rena Callahan an Associate Clinical Professor of Hematology Oncology at University of California, Los Angeles David Geffen School of Medicine and Dr. Shaheenah Dawood, a consultant medical oncologist and professor of oncology at Mediclinic City Hospital, United Arab Emirates, Dubai.

This podcast episode provides an introduction to molecular testing in the diagnosis and treatment of cancer.  Prof. David Hong from MD Anderson Cancer Center, Houston, Texas, USA and Dr Tracy Stockley from the University Health Network, Toronto, Canada discuss optimal testing strategies to identify actionable mutations. The experts discuss genetic testing and why identifying genetic alterations is a critical step to achieving optimal patient care. They share their multidisciplinary perspectives on when to use molecular profiling and which testing methodologies should be used to identify genetic alterations to inform treatment decisions with targeted therapies throughout the patient journey.

In this podcast, the experts deep-dive into two patient case studies of ER+/HER2- metastatic breast cancer, discussing the intricacies of treatment selection and sequencing to maximise outcomes, current data, and what to consider when adjusting dosage or switching treatments. Dr. Rena Callahan an Associate Clinical Professor of Hematology Oncology at University of California, Los Angeles David Geffen School of Medicine and Dr. Shaheenah Dawood, a consultant medical oncologist and professor of oncology at Mediclinic City Hospital, United Arab Emirates, Dubai discuss oral SERDs, a novel therapy for ER+/HER2- advanced or metastatic breast cancer.

This podcast series consists of two episodes where expert oncologists Dr Sam Klempner (Massachusetts General Hospital, USA) and Dr Lizzy Smyth (Oxford University Hospitals NHS Foundation Trust, UK) discuss patient cases focusing on gastric and gastroesophageal junction cancer.  In the second episode, Dr Klempner presents a case of a patient with advanced/metastatic gastric cancer.  The two experts discuss biomarker testing such as MMR, HER2, PD-1 and CLDN 18.2. They also discuss treatment options, CPS scoring and test selection plus recent clinical trial data that are practice changing.

This podcast series consists of two episodes where expert oncologists Dr Sam Klempner (Massachusetts General Hospital, USA) and Dr Lizzy Smyth (Oxford University Hospitals NHS Foundation Trust, UK) discuss patient cases focusing on gastric and gastroesophageal junction cancer.  In this first episode, Dr Smyth presents a case of operable localised gastric cancer.  The two experts discuss the importance of MMR biomarker testing And CROSS VS FLOT management approaches. They refer to data from recent clinical trials in upper gastrointestinal cancer such as MATTERHORN, NEONIPIGA, INFINITY, KEYNOTE-811 and KEYNOTE-585 and how data might impact clinical management. 

In this podcast, the experts give an overview of  the EMERALD trial  and present elacestrant as the first, and currently only, oral SERD to be FDA approved. They focus on the efficacy results and landmark analysis not only according to the duration of CDK4/6i prior treatment but also to the presence/absence of ESR1 mutation. Experts also provide a brief discussion on EMERALD trial safety results. The discussion ends with a look at the current treatment landscapeand future perspective for oral SERDs in ER+/HER2- advanced or metastatic breast cancer. Dr.Rena Callahan an Associate Clinical Professor of Hematology Oncology at University of California, Los Angeles David Geffen School of Medicine and Dr.Shaheenah Dawood, a consultant medical oncologist and professor of oncology at Mediclinic City Hospital, United Arab Emirates, Dubai explore new endocrine therapies for ER+/HER2- advanced or metastatic breast cancer. More specifically, they discuss  oral SERDs efficacy and safety profile as well as their place in treatment landscape 

In this podcast GU NURSES CONNECT members Brenda Martone and Jennifer Sutton discuss the nurse role in managing treatment intensification for metastatic castration sensitive prostate cancer(mCSPC) patients with triplet therapy of ADT + docetaxel + a novel hormonal agent (NHA).  They focus on patient selection, AE management and drug-drug interactions.  The experts discuss key data from the PEACE 1 and ARASENS trials of triplet therapy with abiraterone and darolutamide respectively, in combination with ADT and docetaxel. They discuss the importance of the nurse role in communicating and educating the patient about the benefits and risks of different triplet regimens.  They debate whether triplet therapy should be the new standard of care for all mCSPC patients and discuss the patient subgroups that benefit the most from early treatment intensification.

This podcast episode discusses treatment sequencing in advanced metastatic colorectal cancer (mCRC) patients, third line and beyond.  Dr Shubham Pant from MD Anderson Cancer Center, Houston Texas USA and Dr Jenny Seligmann from the University of Leeds, UK discuss treatment considerations in these patients and evaluate recent data.  The experts discuss the treatments currently approved at third line – regorafenib and TAS-102 (trifluridine/tipiracil).  They also reflect on data presented at ASCO GI 2023 from the SUNLIGHT trial which studied the use of TAS-102 plus bevacizumab as third-line treatment in refractory colorectal cancer and where this treatment may fit into the treatment sequence in the future.  They also look at data from the FRESCO-2 trial which was presented at ESMO 2022 and studied fruquintinib in the later line mCRC setting..  The discussion then moves to treatments for molecularly selected mCRC patients with the MOUNTAINEER trial where a combination of trastuzumab and tucatinib was studied.  Finally, they discuss EGFR rechallenge and data from the CRICKET and CHRONOS trials. 

Assoc. Prof. Shilpa Gupta and Dr Fabio Schutz, discuss early treatment intensification with triplet therapy for metastatic castration-sensitive prostate cancer (mCSPC) in this GU CONNECT podcast. The experts discuss how to apply key data from the PEACE 1 and ARASENS trials of triplet therapy with abirateroneand darolutamide respectively, in combination with ADT and docetaxel into their clinical practice. They debate whether triplet therapy should be the new standard of care for all patients and discuss the patient subgroups that benefit the most from early treatment intensification. A number of patient scenarios are considered alongside the efficacy of the novel hormonal combinations, adverse event profiles, drug to drug interactions, volume of disease, age, comorbidities and patient risk.

Dr Tanya Dorff, a Medical Oncologist from the City of Hope Comprehensive Cancer Center and Dr Neeraj Agarwal, Medical Oncologist and Director of the Genitourinary Oncology Program at the Huntsman Cancer Institute, University of Utah in the United States discuss the efficacy and safety data of combination therapy with PARPi and NHAs, incorporating the latest data presented at ASCO GU 2023 and the impact for the treatment of patients with mCRPC in this GU CONNECT podcast. In this podcast, the experts discuss the updated survival analysis from the PROPEL study of olaparib and abiraterone which demonstrated a benefit in an all-comer mCRPC population and the second interim analysis from the MAGNITUDE study which showed a benefit of niraparib plus abiraterone in mCRPC patients with homologous recombination repair alterations. They also discuss the differing trial results and how these compare to the most recent data presented from the TALAPRO-2 trial of talazoparib plus enzalutamide which showed a benefit in a biomarker unselected population. The experts consider how this combination therapy may be implemented in clinical practice in the future pending regulatory approval of the combinations.

Prof. Dr James Harding, Medical Oncologist at Memorial Sloan Kettering Cancer Center and Prof. Dr Sammy Saab, Gastroenterologist and Transplant Hepatologist at the David Geffen School of Medicine, both from the USA, discuss the treatment options for advanced hepatocellular carcinoma (HCC) patients who are not eligible for immunotherapy (IO) first line. In this podcast, the experts give an overview of the current systemic treatment options for patients by looking into the results from different clinical trials and current guidelines, as the field is rapidly evolving since 2017. They discuss the patient cohorts who are not eligible for IO in first line, such as patients with underlying auto-immunity, impaired organ function and patients who decline IO. The experts discuss the efficacy and safety data from the SHARP and Asia Pacific trials of sorafenib and from the REFLECT trial of lenvatinib, which are both tyrosine kinase inhibitors (TKIs) and available for the aforementioned patient cohorts. They also present their approach to toxicity management for patients receiving those TKIs.